OVERVIEW

Precision Medicine in Severe Asthma: How Phenotypes and Endotypes Guide Treatment Decisions is organized by Medical Communications Media (MCM), Inc.

Release Date: Sep 13, 2019
Credit Expiration Date: Sept 13, 2020.

Accreditation:
The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™.
American Board of Internal Medicine Maintenance of Certification (from ABIM):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points.

Description:
Despite advances in understanding the drivers of severe asthma, rates of hospitalization and mortality due to asthma have not changed significantly in the last two decades. It’s only recently as the medical community has become better at identifying specific asthma endotypes and phenotypes that we’ve seen the rise of unique therapies targeting specific disease pathways. This activity will break down the differences between Type 2 and non-Type 2 asthma and discuss how making that differentiation in severe asthma patients has a profound impact on treatment pathways.

Learning Objectives:
Upon completion of this educational activity, the participant should be able to:
• Review the benefits and limitations of traditional asthma therapy (eg, ICS, LABAs, LAMAs, and LTRAs) for severe asthma phenotypes/endotypes.
• Compare new and emerging phenotype/endotype-targeted agents for severe asthma.
• Develop individualized treatment plans for patients with severe uncontrolled asthma.